relenza crushes the opposition, page-4

Thanks for that Dank. All the more reason to push IV Zanamivir and LANI to cover systemic and high-affinity/low-dose oral applications to take most of the flu market with a pharma partner interested in driving market penetration. With the likely Relenza production about 2 million courses/month heading for double that by the end of the year, GSK may be quietly turning over a new leaf, especially with a new CEO. No doubt BTA are increasingly confident of a settlement now well in excess of the low range $108M given recent developments have verified their earlier position.